PL EN


Preferences help
enabled [disable] Abstract
Number of results
Journal
2010 | 3 | 29-35
Article title

miR-122 silencing a novel therapy for HCV infections?

Content
Title variants
Languages of publication
EN
Abstracts
EN
Hepatitis C (HCV) infection is one of major epidemiological, medical and social concerns in the modern world. In Poland, around 700 000 people have HCV, worldwide the number is as high as 200 million. Current treatment consists of pegylated interferon-alpha and ribavirin, but is limited by the resistance of the viral strains, adverse effects, and high costs. Since HCV infection is a major cause of liver cirrhosis and hepatocellular carcinoma, it is necessary to develop novel antiviral compounds with improved virological response and reduced toxicity. In this article, we describe the results of recent trials to fight the HCV infection using an antagonising miR-122 oligo-LNA probe in primates.
Keywords
Journal
Year
Issue
3
Pages
29-35
Physical description
References
Document Type
REVIEW
Publication order reference
Agata Tyczewska, Gregor Mendel Institute of Molecular Plant Biology, Dr. Bohr-Gasse 3, 1030 Vienna, Austria
YADDA identifier
bwmeta1.element.element-from-psjc-82611240-35b7-3f0d-8425-0af2700fe05a
Identifiers
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.